Deciphera Pharmaceuticals Inc Stock News

NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has priced an underwritten public offering of 5.25 million shares at $10.00 per share, for gross proceeds of $150 million. The offer price represents a d

Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.

Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.

Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.

The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong

The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the last trading session, 1.13 million shares of the Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) were traded, and its beta was 1.55. Most recently the company’s share price was $7.08, and it changed around $0.21 or 3.06% from the last close, which brings the market valuation of the company to $439.95M. DCPH currently trades at a … Why Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Is A Stock Not To Be Discarded In 2022 Read More »

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of t

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) price closed lower on Monday, February 28, dropping -4.58% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $8.08, with intraday deals fluctuated between $7.3804 and $8.08. … Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Is Down -4.58% – Can It Revive? Read More »

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared to $0.69 from the ye